

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Koichi ISHIGURO et al. : ATTN: APPLICATION BRANCH  
Serial No. NEW :  
Filed September 11, 1998 : Attorney Docket No.  
1416/OP551PCUS  
ANTI-PHOSPHORYLATED TAU PROTEIN  
ANTIBODIES AND METHODS FOR DETECTING  
ALZHEIMER'S DISEASE WITH THE USE OF  
THE SAME

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents,  
Washington, D.C. 20231

Sir:

Pursuant to the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicants request consideration of (X) the references listed on the attached Form PTO-1449 and/or ( ) the additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No. PCT/JP97/00804.

1. This Information Disclosure Statement is submitted:

- a. (X) (X) within 3 months of the filing date of the above-identified application, or ( ) within 3 months of entry into National stage prosecution of a International application, or ( ) before the mailing date of the first Office Action on the merits, and thus:

(X) no certification and/or fee is required.

- b. ( ) after the events of above paragraph 1a and prior to the mailing date of a final Office Action or Notice

of Allowance, and thus:

- ☐ the certification of paragraph 2 below is provided,  
or
- ☐ a fee of \$.00 is enclosed.

c. ☐ after the mailing date of a final Office Action or a Notice of Allowance and prior to payment of the issue fee, and thus:

- ☐ the certification of paragraph 2 below is provided,  
and
- ☐ a Petition and fee of \$.00 are enclosed.

2. It is hereby certified:

- ☐ that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following additional information (including any co-pending or abandoned U.S. application, prior uses and/or sales, etc.) is requested:

4. For each non-English language reference listed on the attached Form PTO-1449:

- ☐ reference is made to an English language translation submitted herewith, and/or

- ( ) reference is made to a foreign patent office search report (in the English language) submitted herewith, and/or
  - ( ) reference is made to an English language translation of a foreign patent office search report submitted herewith, and/or
  - ( ) reference is made to the concise explanation contained in the specification of the present application at page(s), and/or
  - ( ) reference is made to the concise explanation set forth below:
5. ( ) Applicants also offer the following comments for the Examiner's consideration:
6. (X) Also enclosed is a copy of the International Search Report citing these references.

Respectfully submitted,

Koichi ISHIGURO et al.

By: Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C.  
Telephone No. (202) 721-8200

September 11, 1998

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: September 11, 1998

ATTY DOCKET NO.  
1416/OP551PCUSSERIAL NO.  
NEWAPPLICANT  
Koichi ISHIGURO et al.FILING DATE  
September 11, 1998

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Proc. Natl. Acad. Sci., Vol. 89, (1992), B. Lichtenberg-Kraag "Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau" pp. 5384-5388, Abstract.
	AB	Neurobiology of Aging, Vol. 16, No. 3, (1995) R. Nuydens "Neuronal Kinase Stimulation Leads to Aberrant Tau Phosphorylation and Neurotoxicity" pp. 465-477, Abstract.
	AC	Biochemical Journal, Vol. 301, (1994), M. Goedert "Epitope mapping of Monoclonal antibodies to the paired helical filaments of Alzheimer's Disease" pp. 871-877, Abstract.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.